From Wikipedia, the free encyclopedia
Jump to: navigation, search
Obinutuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD20
Clinical data
Legal status
Pharmacokinetic data
Half-life 28.4 days
CAS number 949142-50-1 N
ATC code L01XC15
UNII O43472U9X8 YesY
KEGG D09321 YesY
Chemical data
Formula C6512H10060N1712O2020S44 
Mol. mass 146.1 kDa
 N (what is this?)  (verify)

Obinutuzumab (called afutuzumab until 2009[1]) is a humanized monoclonal antibody, originated by Glycart Biotechnology AG and developed by Biogen Idec, Chugai Pharmaceutical Co., and Hoffmann-La Roche Inc. for the treatment of lymphoma.[2] It acts as an immunomodulator.[3][4]

Obinutuzumab targets CD20 and kills B cells.[2]

Obinutuzumab was approved under the tradename Gazyva by the US FDA in 2013, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients. Patients treated with Gazyva had median survival of 23 months before death or disease progression, compared with 11.1 months for patients on chemotherapy alone.[5]

UK availability[edit]

In October 2014, NICE announced that NHS England would not fund use of the drug, due to data uncertainties in Roche's application.[6]


  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  2. ^ a b Robak, T (2009). "GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies". Current opinion in investigational drugs (London, England : 2000) 10 (6): 588–96. PMID 19513948. 
  3. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Afutuzumab, American Medical Association.
  4. ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  5. ^ Associated Press, published in the New York Times. November 1, 2013 F.D.A. Clears New Cancer-Fighting Drug From Roche
  6. ^ "NICE denies Roche cancer drug due to ‘data uncertainties’". PM Live. Retrieved 3 October 2014.